Clinical trial

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

NCT06764056

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-01-01

PhaseNA

Study timeline

Study start (estimated)2025-01-01Date precision: month

Registry last updated2025-01-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metabolic Associated Fatty Liver Diseaseunresolved

Metabolic Associated-dysfunction Steatohepatitis (MASH)unresolved

Obesityunresolved

Interventions

semaglutideDRUG · verified · RxNorm: semaglutide

DietOTHER

Sponsors & collaborators

Institut universitaire de cardiologie et de pneumologie de Québec, University Lavallead sponsor

Mapped research locations

QuébecQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06764056 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.